TROPOS Study Site 106
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PI, Site
NCT05975905: A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

Active, not recruiting
2
113
Europe, US, RoW
Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
Keros Therapeutics, Inc.
Pulmonary Arterial Hypertension
06/25
01/27
NCT05120596: First in Human Study of T3P-Y058-739 (T3P)

Recruiting
1/2
100
Europe
Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT)
T3 Pharmaceuticals AG
Advanced Solid Tumor
02/26
10/26

Download Options